The essence of MAH — "whoever holds it, is responsible"

The Marketing Authorization Holder (MAH) system separates holding the drug approval number from the manufacturing licence. Under the old "bundled" system, only manufacturers could hold the approval number — "whoever manufactures, holds". The MAH system lets research institutions and other entities without manufacturing facilities independently hold the approval number and bring a product to market through contract manufacturing — "whoever holds, is responsible (and need not manufacture)".

But with the right comes heavier responsibility: the MAH bears lifecycle liability, and remains the first-responsible party regardless of who manufactures or sells the drug. That liability cannot be transferred or reduced by delegation.

MAH eligibility

Who can be an MAH?

  • Domestic applicants: enterprise legal persons and research institutions (including non-enterprise research institutes) established in China.
  • Foreign applicants: a foreign MAH must appoint a Chinese enterprise legal person as agent, jointly and severally liable with the MAH.
  • Excluded: natural persons (China, unlike some US FDA policies, does not allow individuals to be MAHs).

Core qualification requirements

  • Quality management capability: a quality management system covering the full lifecycle, whether or not it manufactures.
  • Risk control capability: a pharmacovigilance system, adverse-reaction monitoring and recall capability.
  • Compensation capability: usually satisfied through drug-quality liability insurance.

MAH transfer — trading the approval number

The MAH system permits transferring marketing authorization between holders — effectively a market in drug approval numbers, and one of its most commercially valuable features. A research institution can transfer the MAH of an NDA-approved drug to a large company with strong manufacturing and commercial capability, monetising its R&D.

Key legal points of MAH transfer

  • Subject of transfer: the marketing authorization (approval number), not a simple asset sale — the transferee takes on full lifecycle liability, not just the right to sell.
  • Conditions: the transferee must satisfy MAH requirements and pass authority review.
  • Procedure: joint supplementary application to CDE → technical review → GMP conformity check of the transferee → approval. An unapproved transfer has no legal effect.
  • Post-transfer liability: the transferee assumes full MAH responsibility, but liability for quality problems in products sold before the transfer should be expressly allocated in the transfer agreement.

Liability allocation in contract manufacturing

Where the MAH contracts manufacturing to a CMO, the parties must sign a contract-manufacturing agreement and a quality agreement — the key legal documents for managing production and protecting the MAH.

  • Mandatory content of the quality agreement: each party's responsibilities for raw-material procurement and testing, production monitoring, and release standards and authority — especially the qualified person's independent final-release right.
  • Non-transferability of external liability: no matter how much quality responsibility the CMO assumes, the MAH is always the first-responsible party toward patients and regulators, and cannot evade external liability by blaming the CMO. The MAH may recover from the CMO under the contract after compensating victims or regulators.
  • Multiple CMOs: an MAH may split different stages (API vs. finished product) across CMOs, but must ensure seamless quality management and a complete overall system.

Cross-province MAH coordination

When the MAH and CMO are in different provinces (the norm — e.g. MAH in Beijing, CMO in Jiangsu), regulatory coordination becomes a real challenge:

  • Information sharing: the two provincial drug authorities must establish shared-information and joint-inspection mechanisms.
  • Territorial supervision of the CMO: the CMO's province supervises its GMP compliance but generally does not issue orders directly to the MAH.
  • Our role: establishing liaison mechanisms, protecting the MAH's rights during CMO inspections, and reconciling inconsistent enforcement standards between provinces.

Our core services

  1. MAH eligibility assessment: a gap analysis of quality-management, risk-control and compensation capability.
  2. Contract-manufacturing and quality-agreement drafting: commercially reasonable, legally enforceable liability allocation.
  3. MAH transfers: end-to-end support from due diligence and documents to authority communication and transition.
  4. Annual-report compliance: internal processes for timely MAH annual reports.
  5. Cross-province coordination: regulatory-communication strategy for cross-province MAH-CMO relationships.